A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo asFirst-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Juncti
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
July 25, 2018
End Date
October 31, 2024
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
July 25, 2018
End Date
October 31, 2024